Liraglutide vs Mod GRF 1-29

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

Full details →

Mod GRF 1-29

Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.

Full details →

Side-by-Side Comparison

AspectLiraglutideMod GRF 1-29
MechanismBinds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects.Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity.
Typical DosageSaxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily.Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects.
AdministrationSubcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications.Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version.
Side EffectsNausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use.Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention.
Best For

What They Have in Common

Both Liraglutide and Mod GRF 1-29 are commonly used for:

Key Differences

Ready to Learn More?